| 0.5394 0.069 (14.77%) | 08-21 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.63 |
1-year : | 0.73 |
| Resists | First : | 0.53 |
Second : | 0.63 |
| Pivot price | 0.47 |
|||
| Supports | First : | 0.46 |
Second : | 0.42 |
| MAs | MA(5) : | 0.49 |
MA(20) : | 0.47 |
| MA(100) : | 0.61  |
MA(250) : | 0.74 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 69 |
D(3) : | 64.1 |
| RSI | RSI(14): 61.1 |
|||
| 52-week | High : | 2.05 | Low : | 0.28 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ KTTA ] has closed above the upper band by 13.4%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 34.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.54 - 0.54 | 0.54 - 0.55 |
| Low: | 0.47 - 0.48 | 0.48 - 0.48 |
| Close: | 0.53 - 0.54 | 0.54 - 0.54 |
Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment. These facilities are designed to offer business support, employing trained pharmacists to administer intravenous ketamine infusions. Founded in 2020, the corporation's primary operations are based in Miami Beach, Florida.
Fri, 21 Aug 2026
Pasithea Therapeutics Received Notice of Noncompliance - TradingView
Fri, 21 Aug 2026
Pasithea (NASDAQ: KTTA) gets Nasdaq reprieve before possible delisting - Stock Titan
Fri, 14 Aug 2026
Pasithea Therapeutics Corp. Q2 2026: Net loss $(5.27M), EPS $(0.16) — 10-Q Summary - TradingView
Fri, 14 Aug 2026
Vivo Opportunity entities disclose 9.99% Pasithea Therapeutics (KTTA) holdings via warrants and stock - Stock Titan
Fri, 07 Aug 2026
Pasithea Therapeutics Corp. SEC Filing (Aug 7, 2026) - Stock Titan
Tue, 21 Jul 2026
Pasithea Therapeutics Announces ESMO 2026 Poster Presentation of Phase I PAS-004 Study in Advanced Solid Tumors - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 33 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 1.1 (%) |
| Held by Institutions | 62.7 (%) |
| Shares Short | 243 (K) |
| Shares Short P.Month | 312 (K) |
| EPS | -1.42 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.2 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -31.5 % |
| Return on Equity (ttm) | -58.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.52 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -17 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -0.38 |
| PEG Ratio | 0 |
| Price to Book value | 0.24 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.07 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|